PCP: Difference between revisions
CSV import |
No edit summary |
| (One intermediate revision by the same user not shown) | |
(No difference)
| |
Latest revision as of 13:04, 18 March 2025
PCP or Phencyclidine is a dissociative drug, known for its mind-altering effects. It was originally developed in the 1950s as a surgical anesthetic. However, due to the severe side effects, its use for humans was discontinued in the 1960s. Today, it is classified as a Schedule II drug in the United States, indicating a high potential for abuse and addiction.
History[edit]
Phencyclidine was first synthesized in 1926, and later developed by Parke-Davis in the 1950s as an intravenous anesthetic. Its use in humans was discontinued in the 1960s due to the high incidence of postoperative dysphoria and hallucinations.
Pharmacology[edit]
PCP is a NMDA receptor antagonist, which blocks the activity of the NMDA receptor, disrupting the normal functioning of the brain. It also interacts with other receptors in the brain, which can lead to a variety of effects.
Effects[edit]
The effects of PCP can vary greatly depending on the dose, route of administration, and individual user. They can range from feelings of detachment and dissociation, to hallucinations, delusions, and severe agitation. In high doses, PCP can cause seizures, coma, and death.
Abuse and Addiction[edit]
PCP is a highly addictive drug. Chronic use can lead to physical dependence and psychological addiction. Withdrawal symptoms can include cravings, depression, and anxiety.
Treatment[edit]
Treatment for PCP addiction typically involves a combination of medical detoxification and behavioral therapy. Medications may be used to manage withdrawal symptoms and prevent relapse.


